Claire Gerber1,2, Xuan Cai1, Jungwha Lee1, Timothy Craven3, Julia Scialla4, Nao Souma1, Anand Srivastava1,2, Rupal Mehta1,2, Amanda Paluch5, Alexander Hodakowski1, Rebecca Frazier2, Mercedes R Carnethon5, Myles Selig Wolf4, Tamara Isakova6,2. 1. Center for Translational Metabolism and Health, Institute for Public Health and Medicine. 2. Division of Nephrology and Hypertension, Department of Medicine, and. 3. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina; and. 4. Division of Nephrology, Department of Medicine, Duke University Medical Center, Duke University, Durham, North Carolina. 5. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 6. Center for Translational Metabolism and Health, Institute for Public Health and Medicine, tamara.isakova@northwestern.edu.
Abstract
BACKGROUND AND OBJECTIVES: Type 2 diabetes and associated CKD disproportionately affect blacks. It is uncertain if racial disparities in type 2 diabetes-associated CKD are driven by biologic factors that influence propensity to CKD or by differences in type 2 diabetes care. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of 1937 black and 6372 white participants of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to examine associations of black race with change in eGFR and risks of developing microalbuminuria, macroalbuminuria, incident CKD (eGFR<60 ml/min per 1.73m2, ≥25% decrease from baseline eGFR, and eGFR slope <-1.6 ml/min per 1.73 m2 per year), and kidney failure or serum creatinine >3.3 mg/dl. RESULTS: During a median follow-up that ranged between 4.4 and 4.7 years, 278 black participants (58 per 1000 person-years) and 981 white participants (55 per 1000 person-years) developed microalbuminuria, 122 black participants (16 per 1000 person-years) and 374 white participants (14 per 1000 person-years) developed macroalbuminuria, 111 black participants (21 per 1000 person-years) and 499 white participants (28 per 1000 person-years) developed incident CKD, and 59 black participants (seven per 1000 person-years) and 178 white participants (six per 1000 person-years) developed kidney failure or serum creatinine >3.3 mg/dl. Compared with white participants, black participants had lower risks of incident CKD (hazard ratio, 0.73; 95% confidence intervals, 0.57 to 0.92). There were no significant differences by race in eGFR decline or in risks of microalbuminuria, macroalbuminuria, and kidney failure or of serum creatinine >3.3 mg/dl. CONCLUSIONS:Black participants enrolled in a randomized controlled trial had lower rates of incident CKD compared with white participants. Rates of eGFR decline, microalbuminuria, macroalbuminuria, and kidney failure did not vary by race.
RCT Entities:
BACKGROUND AND OBJECTIVES:Type 2 diabetes and associated CKD disproportionately affect blacks. It is uncertain if racial disparities in type 2 diabetes-associated CKD are driven by biologic factors that influence propensity to CKD or by differences in type 2 diabetes care. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of 1937 black and 6372 white participants of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to examine associations of black race with change in eGFR and risks of developing microalbuminuria, macroalbuminuria, incident CKD (eGFR<60 ml/min per 1.73m2, ≥25% decrease from baseline eGFR, and eGFR slope <-1.6 ml/min per 1.73 m2 per year), and kidney failure or serum creatinine >3.3 mg/dl. RESULTS: During a median follow-up that ranged between 4.4 and 4.7 years, 278 black participants (58 per 1000 person-years) and 981 white participants (55 per 1000 person-years) developed microalbuminuria, 122 black participants (16 per 1000 person-years) and 374 white participants (14 per 1000 person-years) developed macroalbuminuria, 111 black participants (21 per 1000 person-years) and 499 white participants (28 per 1000 person-years) developed incident CKD, and 59 black participants (seven per 1000 person-years) and 178 white participants (six per 1000 person-years) developed kidney failure or serum creatinine >3.3 mg/dl. Compared with white participants, black participants had lower risks of incident CKD (hazard ratio, 0.73; 95% confidence intervals, 0.57 to 0.92). There were no significant differences by race in eGFR decline or in risks of microalbuminuria, macroalbuminuria, and kidney failure or of serum creatinine >3.3 mg/dl. CONCLUSIONS: Black participants enrolled in a randomized controlled trial had lower rates of incident CKD compared with white participants. Rates of eGFR decline, microalbuminuria, macroalbuminuria, and kidney failure did not vary by race.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Kira Evans; Josef Coresh; Lori D Bash; Tiffany Gary-Webb; Anna Köttgen; Kathryn Carson; L Ebony Boulware Journal: Nephrol Dial Transplant Date: 2010-08-05 Impact factor: 5.992
Authors: Miriam S Udler; Girish N Nadkarni; Gillian Belbin; Vaneet Lotay; Christina Wyatt; Omri Gottesman; Erwin P Bottinger; Eimear E Kenny; Inga Peter Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121
Authors: Bessie A Young; Wayne J Katon; Michael Von Korff; Greg E Simon; Elizabeth H B Lin; Paul S Ciechanowski; Terry Bush; Malia Oliver; Evette J Ludman; Edward J Boyko Journal: J Am Soc Nephrol Date: 2004-11-24 Impact factor: 10.121
Authors: Rebecca Thorsness; Shailender Swaminathan; Yoojin Lee; Benjamin D Sommers; Rajnish Mehrotra; Kevin H Nguyen; Daeho Kim; Maricruz Rivera-Hernandez; Amal N Trivedi Journal: J Am Soc Nephrol Date: 2021-04-01 Impact factor: 14.978
Authors: Julia Kerschbaum; Michael Rudnicki; Alexander Dzien; Christine Dzien-Bischinger; Hannes Winner; Hiddo Lambers Heerspink; László Rosivall; Andrzej Wiecek; Patrick B Mark; Susanne Eder; Sara Denicolò; Gert Mayer Journal: Sci Rep Date: 2020-11-12 Impact factor: 4.379